ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0953

An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis

Kaitlin Quinn1, Sara Monti2, Georgia Lanier3, Maria Bjork Viðarsdóttir4, Robin Christensen5, David R.W. Jayne6, Carol Langford7, Alfred Mahr8, Christian Pagnoux9, Gunnar Tomasson10 and Peter Merkel11, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2University of Pavia, Pavia, Italy, 3n/a, Sherborn, MA, 4n/a, Reykjavik, Iceland, 5Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, 6University of Cambridge, Cambridge, United Kingdom, 7Cleveland Clinic, Moreland Hills, OH, 8Kantonsspital St. Gallen, St.Gallen, Switzerland, 9Mount Sinai Hospital, Toronto, ON, Canada, 10University of Iceland, Reykjavik, Iceland, 11University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, delphi, Response Criteria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Abstracts: Vasculitis – ANCA-Associated (0952–0955)

Session Type: Abstract Session

Session Time: 9:15AM-9:30AM

Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity. Randomized controlled trials (RCTs) in AAV have used multiple instruments to define active disease or remission as a dichotomous outcome. However, no formal criteria exist to measure treatment response in AAV. This Delphi exercise aimed to reach consensus about which measures are considered by patients and physicians to be most important when assessing treatment response in RCTs in AAV.

Methods: An international 3-round online Delphi exercise was conducted in English. Survey participants included experts in AAV and patients with AAV. Items in the Delphi were based on a systematic literature review of outcome measures in RCTs in AAV, and suggestions from a Steering Committee comprised of vasculitis experts and patients with AAV.

Survey participants were asked to rate (on a scale of 1-9) the importance of each item when assessing response to treatment (improvement) in a RCT in AAV. Items scored 7-9 by ≥70% participants were considered to be highly important, and items scored 1-3 by ≥70% participants were considered to be of limited importance.

Results: 265 participants completed three rounds of the Delphi, including 176 physicians with expertise in AAV and 89 patients with AAV. Physicians were from six continents; the majority from Europe [n=81 (46%)] or North America [n=50 (28%)]. Most physicians specialized in rheumatology [n=105 (60%)] or nephrology [n=50 (28%)]. All physicians were in practice for at least 2 years (two-thirds >10 years) and responsible for managing ≥30 patients with AAV; over half of the physicians managed >75 patients with AAV. Patients with AAV were from four continents, with most located in North America [n=63 (71%)] or Europe [n=23 (26%)] with a diagnosis of GPA [n=71 (80%)] or MPA [n=16 (18%)]. The majority of patients with AAV were female [n=61 (69%)], ages 50-79 years [n=67 (75%)], were diagnosed in the past 10 years [n= 62 (70%)], and were currently on treatment [n=61 (69%)].

The most highly rated items of response (Table 1) involved disease activity [reduction in BVAS, extent of organ involvement, and physician global assessment] and patient-reported outcomes [patient global assessment and health-related quality of life]. Achievement of BVAS ≤1 and BVAS of 0 were highly rated more often by physicians than by patients. Pain and fatigue were highly rated by patients, but not by physicians. Changes on urinalysis and acute phase reactants were highly rated only by patients. Additional items related to organ damage, glucocorticoid tapering, and treatment-related adverse events were highly rated by both patients and physicians. There were no items rated of limited importance by both patients and physicians.

Conclusion: In this Delphi exercise, there was consensus between international experts in AAV and patients with AAV on many items considered important to measure when assessing treatment response in RCTs in AAV. There were also some items rated as highly important by only experts or only patients. These data provide insights into how to evaluate this complex form of vasculitis and will inform the next steps in the development of treatment response criteria in AAV.


Disclosures: K. Quinn, None; S. Monti, None; G. Lanier, None; M. Bjork Viðarsdóttir, None; R. Christensen, None; D. Jayne, ChemoCentryx, 2, 5, GSK, 2, 5, Roche/Genentech, 5, Sanofi-Genzyme, 5, AstraZeneca, 2, Boehringer-Ingelheim, 2, Celgene, 2, InflaRx, 2; C. Langford, None; A. Mahr, Celgene, 2, Chugai, 2, 6, Roche, 6, Amgen, 1, 6; C. Pagnoux, Gsk, 2, 5, 6, Roche, 2, 5, 6, Otuska, 2, Pfizer, 5, 6, Chemocentryx, 2, Astrazeneca, 1; G. Tomasson, None; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9.

To cite this abstract in AMA style:

Quinn K, Monti S, Lanier G, Bjork Viðarsdóttir M, Christensen R, Jayne D, Langford C, Mahr A, Pagnoux C, Tomasson G, Merkel P. An International Delphi Exercise to Identify Items of Importance for Measuring Response to Treatment for ANCA-associated Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/an-international-delphi-exercise-to-identify-items-of-importance-for-measuring-response-to-treatment-for-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-international-delphi-exercise-to-identify-items-of-importance-for-measuring-response-to-treatment-for-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology